MA48594B1 - Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a - Google Patents
Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba aInfo
- Publication number
- MA48594B1 MA48594B1 MA48594A MA48594A MA48594B1 MA 48594 B1 MA48594 B1 MA 48594B1 MA 48594 A MA48594 A MA 48594A MA 48594 A MA48594 A MA 48594A MA 48594 B1 MA48594 B1 MA 48594B1
- Authority
- MA
- Morocco
- Prior art keywords
- alpha5
- gaba
- pam
- ether derivatives
- new
- Prior art date
Links
- LRJJZSXDNXHKQV-UHFFFAOYSA-N 3-(1,2-oxazol-3-yloxy)-1,2-oxazole Chemical class C1=CON=C1OC=1C=CON=1 LRJJZSXDNXHKQV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
L'invention porte sur de nouveaux composés répondant à la formule générale (i), dans laquelle r1, r2, r3, r4, r5, r6, x, y, et z sont tels que décrits dans la description. L'invention porte également sur des compositions comprenant ces composés et sur leurs procédés d'utilisation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16202889 | 2016-12-08 | ||
| PCT/EP2017/081768 WO2018104419A1 (fr) | 2016-12-08 | 2017-12-07 | Nouveaux dérivés d'éther isoxazolyle en tant que gaba a alpha5 pam |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA48594A MA48594A (fr) | 2021-04-28 |
| MA48594B1 true MA48594B1 (fr) | 2022-05-31 |
Family
ID=57530563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA48594A MA48594B1 (fr) | 2016-12-08 | 2017-12-07 | Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US11091471B2 (fr) |
| EP (1) | EP3551627B1 (fr) |
| JP (1) | JP7084405B2 (fr) |
| KR (1) | KR102564643B1 (fr) |
| CN (2) | CN109923113B (fr) |
| AR (1) | AR110498A1 (fr) |
| AU (1) | AU2017373734B2 (fr) |
| CA (1) | CA3040024A1 (fr) |
| CL (1) | CL2019001458A1 (fr) |
| CO (1) | CO2019002692A2 (fr) |
| CR (1) | CR20190268A (fr) |
| DK (1) | DK3551627T3 (fr) |
| ES (1) | ES2910110T3 (fr) |
| HR (1) | HRP20220468T1 (fr) |
| HU (1) | HUE058355T2 (fr) |
| IL (1) | IL267054B (fr) |
| LT (1) | LT3551627T (fr) |
| MA (1) | MA48594B1 (fr) |
| MX (1) | MX388725B (fr) |
| MY (1) | MY200641A (fr) |
| PE (1) | PE20191156A1 (fr) |
| PH (1) | PH12019500664B1 (fr) |
| PL (1) | PL3551627T3 (fr) |
| PT (1) | PT3551627T (fr) |
| RS (1) | RS63106B1 (fr) |
| SI (1) | SI3551627T1 (fr) |
| TW (1) | TWI642666B (fr) |
| UA (1) | UA125524C2 (fr) |
| WO (1) | WO2018104419A1 (fr) |
| ZA (1) | ZA201902225B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA48594B1 (fr) | 2016-12-08 | 2022-05-31 | Hoffmann La Roche | Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a |
| AU2019286312B2 (en) | 2018-06-13 | 2023-08-17 | F. Hoffmann-La Roche Ag | New isoxazolyl ether derivatives as GABA A alpha5 PAM |
| BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| HU231223B1 (hu) * | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
| US12649738B2 (en) | 2020-03-26 | 2026-06-09 | Richter Gedeon Nyrt. | 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators |
| TWI901650B (zh) * | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| US20240425491A1 (en) * | 2021-05-05 | 2024-12-26 | University College Cardiff Consultants Limited | Heteroaryl compounds useful in the treatment of cognitive disorders |
| HU231691B1 (hu) | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| CN116854685A (zh) * | 2022-03-28 | 2023-10-10 | 上海赛默罗生物科技有限公司 | 异噁唑-稠环类衍生物、药物组合物和用途 |
| TW202409022A (zh) | 2022-06-20 | 2024-03-01 | 瑞士商赫孚孟拉羅股份公司 | ６－（（５－甲基－３－（６－甲基吡啶－３－基）異唑－４－基）甲氧基）－ｎ－（四氫哌喃－４－基）嗒𠯤－３－甲醯胺之結晶形式 |
| KR20250092192A (ko) | 2022-10-25 | 2025-06-23 | 에프. 호프만-라 로슈 아게 | 알로가바트 제조 방법 |
| CN121001709A (zh) | 2023-04-24 | 2025-11-21 | 豪夫迈·罗氏有限公司 | 包含6-((5-甲基-3-(6-甲基吡啶-3-基)异噁唑-4-基)甲氧基)-n-(四氢吡喃-4-基)哒嗪-3-甲酰胺的片剂 |
| WO2024251133A1 (fr) * | 2023-06-05 | 2024-12-12 | 武汉人福创新药物研发中心有限公司 | COMPOSÉ HÉTÉROCYCLIQUE EN TANT QUE MODULATEUR DU RÉCEPTEUR α5-GABAA ET SON UTILISATION |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2682301A1 (fr) | 2007-04-18 | 2008-10-30 | Astrazeneca Ab | Composes de xanthine ayant un effet modulateur allosterique positif du recepteur gaba b |
| JP5301557B2 (ja) * | 2007-12-04 | 2013-09-25 | エフ．ホフマン−ラ ロシュ アーゲー | イソオキサゾロ−ピリジン誘導体 |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| US8222246B2 (en) | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
| US8415379B2 (en) | 2009-05-05 | 2013-04-09 | Hoffmann-La Roche Inc. | Pyridines |
| CN103189062B (zh) | 2010-11-05 | 2016-03-23 | 霍夫曼-拉罗奇有限公司 | 活性药物化合物用于治疗中枢神经系统病症的用途 |
| HRP20192323T1 (hr) * | 2011-09-15 | 2020-03-20 | F. Hoffmann - La Roche Ag | Novi derivati dihidrokinolin-2-ona |
| CN107922409A (zh) | 2015-08-17 | 2018-04-17 | 鲁宾有限公司 | 作为parp抑制剂的杂芳基衍生物 |
| TWI782395B (zh) | 2016-01-08 | 2022-11-01 | 美商西建公司 | 抗增生化合物，及其醫藥組合物及用途 |
| LT3399984T (lt) | 2016-01-08 | 2023-11-10 | Arcus Biosciences, Inc. | 5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas |
| MA48594B1 (fr) | 2016-12-08 | 2022-05-31 | Hoffmann La Roche | Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a |
-
2017
- 2017-12-07 MA MA48594A patent/MA48594B1/fr unknown
- 2017-12-07 PT PT178166302T patent/PT3551627T/pt unknown
- 2017-12-07 PL PL17816630T patent/PL3551627T3/pl unknown
- 2017-12-07 JP JP2019530755A patent/JP7084405B2/ja active Active
- 2017-12-07 SI SI201731124T patent/SI3551627T1/sl unknown
- 2017-12-07 MX MX2019006696A patent/MX388725B/es unknown
- 2017-12-07 CN CN201780069758.2A patent/CN109923113B/zh active Active
- 2017-12-07 EP EP17816630.2A patent/EP3551627B1/fr active Active
- 2017-12-07 DK DK17816630.2T patent/DK3551627T3/da active
- 2017-12-07 RS RS20220321A patent/RS63106B1/sr unknown
- 2017-12-07 LT LTEPPCT/EP2017/081768T patent/LT3551627T/lt unknown
- 2017-12-07 HR HRP20220468TT patent/HRP20220468T1/hr unknown
- 2017-12-07 MY MYPI2019001529A patent/MY200641A/en unknown
- 2017-12-07 AR ARP170103429A patent/AR110498A1/es active IP Right Grant
- 2017-12-07 CN CN202311216893.9A patent/CN117285525A/zh active Pending
- 2017-12-07 WO PCT/EP2017/081768 patent/WO2018104419A1/fr not_active Ceased
- 2017-12-07 CA CA3040024A patent/CA3040024A1/fr active Pending
- 2017-12-07 KR KR1020197016011A patent/KR102564643B1/ko active Active
- 2017-12-07 AU AU2017373734A patent/AU2017373734B2/en active Active
- 2017-12-07 HU HUE17816630A patent/HUE058355T2/hu unknown
- 2017-12-07 ES ES17816630T patent/ES2910110T3/es active Active
- 2017-12-07 PE PE2019001006A patent/PE20191156A1/es unknown
- 2017-12-07 CR CR20190268A patent/CR20190268A/es unknown
- 2017-12-07 PH PH1/2019/500664A patent/PH12019500664B1/en unknown
- 2017-12-07 UA UAA201907047A patent/UA125524C2/uk unknown
- 2017-12-07 TW TW106142872A patent/TWI642666B/zh active
-
2019
- 2019-03-26 CO CONC2019/0002692A patent/CO2019002692A2/es unknown
- 2019-04-09 ZA ZA2019/02225A patent/ZA201902225B/en unknown
- 2019-05-29 CL CL2019001458A patent/CL2019001458A1/es unknown
- 2019-06-03 IL IL267054A patent/IL267054B/en unknown
- 2019-06-05 US US16/432,584 patent/US11091471B2/en active Active
-
2021
- 2021-07-16 US US17/378,410 patent/US20220411415A1/en not_active Abandoned
-
2024
- 2024-02-28 US US18/590,606 patent/US20240279218A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55131B1 (fr) | Nouveaux composés hétérocycliques | |
| MA53219B1 (fr) | Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase | |
| MA64323B1 (fr) | Inhibiteurs de nlrp3 | |
| MA49560B1 (fr) | Composés cétoniques bicycliques et leurs procédés d'utilisation | |
| WO2019035863A8 (fr) | Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques | |
| MA63458B1 (fr) | Nouveaux dérivés de sulfonamide pyrimidin-2-yl | |
| MA41562A1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
| EP3886883A4 (fr) | Formulations hydrosolubles de cannabinoïdes ou de composés dérivés du cannabis, leurs procédés de fabrication et leurs méthodes d'utilisation | |
| EP4291201A4 (fr) | Composés, compositions et leurs méthodes d'utilisation | |
| MA31597B1 (fr) | Nouveaux herbicides | |
| EP3801551A4 (fr) | Compositions comprenant des composés bisfluoroalkyl-1,4-benzodiazépinone et des agents immunothérapeutiques et leurs méthodes d'utilisation | |
| MA39721A (fr) | Nouvelles héteroaryldihydropyrimidines condensées en position 6 pour le traitement et la prophylaxie d'une infection à virus de l'hépatite b | |
| MA31690B1 (fr) | Nouveaux fongicides | |
| MA31596B1 (fr) | Nouveaux herbicides | |
| MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA32468B1 (fr) | Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k | |
| MA31741B1 (fr) | Derives fongicides de 2-alkylthio-2-quinolinyloxy- acetamide | |
| MA42109B1 (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
| MA33275B1 (fr) | Inhibiteurs de la replication du virus de l'immunodeficience humaine | |
| MA30717B1 (fr) | Derives de pyridin-3-yle en tant qu'agents immunomodulateurs | |
| MA30718B1 (fr) | Derives de pyridin-4-yle en tant qu'agents immunomodulateurs. | |
| MA32711B1 (fr) | Pyrrolidine-2-carboxamides substitues | |
| MA42239B1 (fr) | Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| MA31623B1 (fr) | Nouveaux herbicides |